The Next Drugs: An Atlantic Policy Update on Biosimilars
During the first half of 2017, healthcare has been a topic of significant debate and conflict in Washington, D.C. From conservatives’ mission to ‘repeal and replace’ the Affordable Care Act (ACA) to consistent challenges to the current structure of Medicare and Medicaid, politicians and regulators on both sides of the aisle are aggressively pushing for new policies, updates to outdated regulations, and a means of addressing anti-competitive practices that block access to affordable generic and biosimilar alternatives.
Unsurprisingly, access to affordable medicines is a focal point for these efforts as the pressure of mounting prescription drug costs, especially in the realm of specialty medicines and biologics, is forcing policy makers, regulators, and drug manufacturers to examine the potential benefits of alternatives such as biosimilars. In the United States, generic medicines save consumers over $4 billion every week and biosimilars offer the same potential benefit to consumers that take biologic drugs – which can often cost tens of thousands of dollars per year per patient.
Working in coordination with The Atlantic, an award-winning publication that covers politics, business, and technology, The Biosimilars Council will continue its efforts to educate consumers about biosimilars by bringing together key stakeholders to debate the state and future of biosimilars in the United States at their next event: The Next Drugs: An Atlantic Policy Update on Biosimilars.
Our panel will answer important questions such as…
- What impact will ongoing regulatory and policy considerations have on biosimilars development?
- What can stakeholders anticipating biosimilars expect when it comes to patents and exclusivity?
- What effect will the priorities of leadership in Congress and the Administration have on the industry over the next few years?
The event will be held in the Newseum’s Knight Broadcast Studio on June 7th from 8:00-10:00 AM. If you are not able to join us in person, we encourage you to follow along with the live stream – which will be available on the homepage of The Biosimilars Council website and on The Atlantic’s website.
Additionally, please consider joining The Biosimilars Council from September 12-13, 2017 at the 2017 AAM Biosimilars Council Conference in Washington, D.C. For more information and to register, visit our event page.
Information on past Next Drugs events from The Biosimilars Council and The Atlantic:
The Next Drugs: The Future for Biosimilars, An Atlantic Policy Briefing(March 15, 2017)
Primary Discussion Topic: New guidelines on naming and interchangeability from the U.S. Food and Drug Administration
The Next Drugs: An Atlantic Policy Briefing on Biosimilars (Dec. 7, 2016)
Primary Discussion Topic: The regulatory framework of biosimilars
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.